



February 19, 2020

Dear all

Kowa Company, Ltd.

**Fixed Combination Eye Drop of Ripasudil Hydrochloride Hydrate,
a Rho Kinase Inhibitor, and Brimonidine Tartrate
Started Phase 3 Clinical Studies in Japan
[Developmental code: K-232]**

Kowa Company, Ltd. (Headquarters: Nagoya, Japan, President & CEO: Yoshihiro Miwa, hereafter referred to as “Kowa”) announced that Phase 3 clinical studies of fixed combination eye drop “Ripasudil Hydrochloride Hydrate” (hereafter referred to as “Ripasudil”), a Rho kinase inhibitor, and Brimonidine tartrate (Developmental code: K-232) have started in Japan.

Kowa is developing Ripasudil as a global product. Ripasudil was launched in December 2014 in Japan (Brand name: GLANATEC® ophthalmic solution 0.4%) as the world's first glaucoma drug with Rho kinase inhibitory activity. In addition, Kowa is developing a Phase 2 clinical studies in the U.S. of Ripasudil for corneal endothelial diseases (developmental code: K-321).

K-232 is expected to improve adherence as the first fixed combination eye drop containing Ripasudil for the treatment of glaucoma and ocular hypertension.

■ GLANATEC® Ophthalmic Solution 0.4%

GLANATEC® Ophthalmic Solution 0.4% includes Ripasudil, as an active ingredient, and lowers intraocular pressure by promoting discharge of aqueous humor through a main outflow via trabecular meshwork-Schlemm’s canal as a result of Rho kinase inhibitory activity.

In clinical studies enrolling patients with primary open-angle glaucoma and ocular hypertension in Japan, GLANATEC® Ophthalmic Solution 0.4% has been demonstrated to be effective in lowering intraocular pressure as both mono-therapy and adjunctive therapy along with conventional glaucoma and ocular hypertension drugs.

 <i>Kowa Company, Ltd.</i>	Public Relations Department (Tokyo) (Japanese inquiries only)	3-4-14, Nihonbashi Honcho, Chuo-ku, Tokyo TEL:+81-3-3279-7392
	Headquarters (Nagoya)	Nishiki 3-6-29, Nagoya City